HepaLife BioSystems, Inc. is the developer of HepaMate™, an extracorporeal cell-based bioartificial liver system designed to combine blood detoxification with liver cell therapy to provide whole liver function in patients with the most severe forms of liver failure.

HepaMate™ is comprised of: 

  • a blood plasma separation cartridge;
  • a hollow-fiber bioreactor filled with proprietary porcine liver cells;
  • a charcoal column;
  • an oxygenator;
  • circuit tubing; and
  • plasma reservoir.
These components are assembled into a patented blood/plasma circulation system, which is placed on the HepaDrive™ perfusion platform.
Contact Information

HepaLife Biosystems Inc.
850 3rd Avenue,
Suite 1801
New York, NY 10022
Email: [email protected]

Visit Website